What are the detailed pharmacologic and clinical differences between epinephrine (adrenaline), norepinephrine (noradrenaline), dobutamine, dopamine, milrinone, and vasopressin for vasoactive/inotropic support in critically ill adults?

Vasoactive Agent Comparison for Critically Ill Adults

Norepinephrine is the first-line vasoactive agent for most shock states, particularly septic shock, based on superior safety profile with fewer arrhythmias compared to dopamine, while dobutamine or milrinone serve as first-line inotropes when myocardial dysfunction predominates. 1

Mechanism of Action & Receptor Activity

Vasopressors (Primarily Increase Vascular Tone)

Norepinephrine (Noradrenaline)

• Potent α1-adrenergic agonist with moderate β1 activity
• Increases mean arterial pressure through vasoconstriction
• Modest positive inotropic effect
• Minimal chronotropic effect at therapeutic doses

Vasopressin

• Non-adrenergic V1a receptor agonist
• Direct vasoconstriction independent of catecholamine pathways
• No inotropic or chronotropic effects
• Particularly effective in catecholamine-refractory shock

Dopamine

• Dose-dependent receptor activity:
  • Low doses (2-5 mcg/kg/min): dopaminergic receptors
  • Moderate doses (5-10 mcg/kg/min): β1-adrenergic
  • High doses (>10 mcg/kg/min): α-adrenergic
• Increases heart rate and arrhythmia risk 2
• Clearance 46-168 mL/kg/min in critically ill patients, half-life 5-11 minutes 2

Epinephrine (Adrenaline)

• Non-selective α and β agonist
• Potent vasoconstriction (α1) plus strong inotropy/chronotropy (β1)
• Increases myocardial oxygen demand significantly
• Can worsen lactate levels independent of tissue hypoxia

Inotropes (Primarily Increase Contractility)

Dobutamine

• Selective β1-adrenergic agonist with mild β2 activity
• Increases cardiac output through enhanced contractility 3
• Increases stroke volume without marked tachycardia (though can occur)
• Mild vasodilation from β2 effects reduces afterload
• Onset 1-2 minutes, peak effect up to 10 minutes, half-life 2 minutes 3
• Does not release endogenous norepinephrine 3

Milrinone

• Phosphodiesterase-3 inhibitor (non-adrenergic mechanism)
• Increases contractility AND causes vasodilation (inodilator) 4
• Works independently of β-receptors—effective in patients on β-blockers 5
• Improves diastolic function and reduces filling pressures 4
• Therapeutic plasma concentration: 100-300 ng/mL 4
• Does not increase myocardial oxygen consumption as much as catecholamines

Clinical Application by Shock Type

Septic Shock

First-line: Norepinephrine 1

• The SOAP II trial showed dopamine increased arrhythmic events without survival benefit 1
• Mortality increased during norepinephrine shortages when replaced by phenylephrine/dopamine 1

Second-line options:

• Vasopressin (0.03-0.06 U/min): Add when norepinephrine requirements are high

  • VASST trial: no overall mortality benefit, but potential benefit in less severe shock (norepinephrine <15 mcg/min) 1
  • Synergistic effect with hydrocortisone on survival in some studies 1
  • May reduce need for renal replacement therapy 6

• Epinephrine: Achieves similar shock reversal to norepinephrine, but increases lactate 1

• Dopamine: Reserved ONLY for bradycardic patients due to increased arrhythmia risk 1

Inotropic support for septic myocardial dysfunction:

• Dobutamine remains gold standard 1
• Milrinone alternative, especially with β-blocker use 5
• Network meta-analysis suggested levosimendan and dobutamine associated with survival benefit 1

Cardiogenic Shock

First-line vasopressor: Norepinephrine 1, 5

• SOAP II subgroup analysis: dopamine increased mortality vs norepinephrine in cardiogenic shock 1
• Fewer arrhythmias than dopamine 1

First-line inotrope: Dobutamine or Milrinone 5

• Retrospective data suggest similar outcomes between dobutamine and milrinone 5
• Milrinone preferred when:
  • Patient on β-blockers (works via non-adrenergic mechanism) 5
  • Need afterload reduction (vasodilatory properties)
  • Want to improve diastolic function 4

Critical caveat: Use lowest effective doses for shortest duration—all inotropes increase myocardial oxygen demand, ischemic burden, and arrhythmia risk 5

Hemodynamic Effects Comparison

Agent	MAP	CO	HR	SVR	Key Effect
Norepinephrine	↑↑↑	↑	↔/↑	↑↑↑	Vasoconstriction + mild inotropy
Epinephrine	↑↑↑	↑↑↑	↑↑	↑↑	Potent inotropy + vasoconstriction
Dopamine	↑↑	↑↑	↑↑	↑	Dose-dependent, ↑ arrhythmias
Vasopressin	↑↑	↔	↔	↑↑↑	Pure vasoconstriction
Dobutamine	↔/↓	↑↑↑	↑	↓	Inotropy + mild vasodilation
Milrinone	↓	↑↑	↔/↑	↓↓	Inotropy + vasodilation

Safety Profile & Adverse Effects

Arrhythmia Risk (Highest to Lowest):

1. Dopamine - significantly increased arrhythmias in SOAP II 1
2. Epinephrine - potent chronotropic effects
3. Dobutamine - can cause tachycardia, occasional arrhythmias
4. Milrinone - increased arrhythmias in some trials 1
5. Norepinephrine - lowest arrhythmia risk among catecholamines
6. Vasopressin - no direct cardiac effects

Drugs with positive chronotropic effects may be associated with higher mortality risk 1

Metabolic/Immune Effects:

• Dopamine: decreases prolactin, may reduce lymphocyte count and immune function 1
• Epinephrine/Norepinephrine: may modulate cytokine response, can stimulate bacterial growth 1
• Vasopressin: decreased plasma cytokines more than norepinephrine 1

Practical Dosing Considerations

Norepinephrine: Start 0.05-0.1 mcg/kg/min, titrate to MAP ≥65 mmHg

Vasopressin: Fixed dose 0.03-0.04 U/min (do not titrate beyond 0.06 U/min)

Dopamine: 5-20 mcg/kg/min (avoid as first-line; reserve for bradycardia)

Dobutamine: 2.5-20 mcg/kg/min, titrate to cardiac output/perfusion 3

Milrinone: Loading dose 50 mcg/kg over 10 min (optional), then 0.375-0.75 mcg/kg/min 4

Epinephrine: 0.05-0.5 mcg/kg/min (second-line in most scenarios)

Critical Decision Points

When to add vasopressin to norepinephrine:

• Norepinephrine requirements >15 mcg/min
• Refractory hypotension
• Concern for renal protection (may reduce RRT need) 6
• Patient on corticosteroids (potential synergy) 1

When to choose milrinone over dobutamine:

• Patient on β-blockers
• Need afterload reduction
• Diastolic dysfunction predominates
• Avoid in hypotension (vasodilatory effects)

When to avoid dopamine entirely:

• Any shock state where norepinephrine available 1
• Pre-existing arrhythmias
• Exception: symptomatic bradycardia with shock

Common pitfall: Using epinephrine as first-line in septic shock—while effective for shock reversal, it increases lactate and metabolic derangements without survival benefit over norepinephrine 1

Monitoring Requirements

All vasoactive agents require:

• Continuous arterial blood pressure monitoring
• Central venous access (peripheral extravasation causes tissue necrosis)
• Frequent reassessment and titration to minimal effective dose
• Early invasive hemodynamic monitoring (pulmonary artery catheter) recommended in cardiogenic shock 5

The evidence shows no definitive survival advantage for any single agent 1, so recommendations prioritize safety (arrhythmia risk, organ dysfunction) and hemodynamic appropriateness for the specific shock phenotype.